ReShape End Period Cash Flow from 2010 to 2024

RSLS Stock  USD 4.49  0.06  1.32%   
ReShape Lifesciences End Period Cash Flow yearly trend continues to be comparatively stable with very little volatility. End Period Cash Flow will likely drop to about 4.3 M in 2024. From the period from 2010 to 2024, ReShape Lifesciences End Period Cash Flow quarterly data regression had r-value of (0.57) and coefficient of variation of  80.11. View All Fundamentals
 
End Period Cash Flow  
First Reported
2007-09-30
Previous Quarter
1.2 M
Current Value
843 K
Quarterly Volatility
12.2 M
 
Housing Crash
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check ReShape Lifesciences financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among ReShape Lifesciences' main balance sheet or income statement drivers, such as Interest Expense of 24.7 K, Other Operating Expenses of 26.5 M or Total Operating Expenses of 24.6 M, as well as many indicators such as Price To Sales Ratio of 0.16, Dividend Yield of 0.0 or PTB Ratio of 0.21. ReShape financial statements analysis is a perfect complement when working with ReShape Lifesciences Valuation or Volatility modules.
  
Check out the analysis of ReShape Lifesciences Correlation against competitors.
For more information on how to buy ReShape Stock please use our How to Invest in ReShape Lifesciences guide.

Latest ReShape Lifesciences' End Period Cash Flow Growth Pattern

Below is the plot of the End Period Cash Flow of ReShape Lifesciences over the last few years. It is ReShape Lifesciences' End Period Cash Flow historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in ReShape Lifesciences' overall financial position and show how it may be relating to other accounts over time.
End Period Cash Flow10 Years Trend
Slightly volatile
   End Period Cash Flow   
       Timeline  

ReShape End Period Cash Flow Regression Statistics

Arithmetic Mean11,002,176
Geometric Mean8,115,662
Coefficient Of Variation80.11
Mean Deviation7,135,631
Median7,927,240
Standard Deviation8,814,385
Sample Variance77.7T
Range25.5M
R-Value(0.57)
Mean Square Error56.3T
R-Squared0.33
Significance0.03
Slope(1,126,668)
Total Sum of Squares1087.7T

ReShape End Period Cash Flow History

20244.3 M
20234.6 M
2022M
202122.8 M
2020M
2019M
20185.5 M

About ReShape Lifesciences Financial Statements

ReShape Lifesciences shareholders use historical fundamental indicators, such as End Period Cash Flow, to determine how well the company is positioned to perform in the future. Although ReShape Lifesciences investors may analyze each financial statement separately, they are all interrelated. The changes in ReShape Lifesciences' assets and liabilities, for example, are also reflected in the revenues and expenses on on ReShape Lifesciences' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
Last ReportedProjected for Next Year
End Period Cash Flow4.6 M4.3 M

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Explore Investing Ideas  

Additional Tools for ReShape Stock Analysis

When running ReShape Lifesciences' price analysis, check to measure ReShape Lifesciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ReShape Lifesciences is operating at the current time. Most of ReShape Lifesciences' value examination focuses on studying past and present price action to predict the probability of ReShape Lifesciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ReShape Lifesciences' price. Additionally, you may evaluate how the addition of ReShape Lifesciences to your portfolios can decrease your overall portfolio volatility.